Orphanet Journal of Rare Diseases | New drug development for Erythropoietic Protoporphyria: Trial design and patient perspective analysis

Recommend:

This article systematically analyzes the current clinical trial designs for Erythropoietic Protoporphyria (EPP), highlighting the non-comparability of efficacy and safety data across different drugs, and raises ethical and methodological challenges from a patient-centered perspective.

 

Literature Overview

This article, titled 'New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective', published in Orphanet Journal of Rare Diseases, reviews recent advances in drug development for erythropoietic protoporphyria (EPP). It focuses on clinical trial protocols for afamelanotide, dersimelagon, bitopertin, and cimetidine, evaluating their comparability in terms of efficacy endpoints, subject populations, trial design, and safety. The study notes that current trial designs exhibit significant heterogeneity in endpoints and population selection, making direct efficacy comparisons between drugs challenging. Additionally, ethical concerns exist, such as requiring patients to be exposed to sunlight during treatment to induce symptoms, which may cause discomfort and psychological stress. The research calls for trial designers, ethics committees, and regulatory agencies to improve trial methodologies, using afamelanotide as a control for direct comparisons to generate more clinically meaningful data.

Background

EPP is a group of rare inherited metabolic disorders caused by mutations in genes involved in the heme biosynthesis pathway. Its main feature is the accumulation of protoporphyrin IX (PPIX) in red blood cells and blood vessels, leading to severe phototoxic reactions within minutes of visible light exposure. There are three subtypes: EPP1 (caused by FECH mutations), XLEPP (caused by gain-of-function ALAS2 mutations), and EPP2 (caused by CLPX mutations). Approximately 5% of EPP patients develop cholestatic liver failure, and most exhibit mild anemia or iron metabolism abnormalities. Afamelanotide is the only approved treatment currently available, acting by activating the MC1R receptor to increase eumelanin production and reduce phototoxic reactions. However, as it is administered via subcutaneous implant, it is not suitable for children and offers no therapeutic benefit for liver disease, highlighting the urgent need for new therapies. Recently, new drugs such as dersimelagon (MC1R agonist), bitopertin (GlyT1 inhibitor), and cimetidine (potentially acting via ALAS2 inhibition) have entered clinical trials, but their trial designs often use placebo controls with inconsistent endpoints, making direct comparisons with afamelanotide difficult. Moreover, certain selection criteria based on patients' psychological and physiological status may exclude more severely affected individuals, limiting the generalizability of results.

 

A practical tool for quickly mapping DNA or RNA sequences to the genome.

Learn More

 

Research Methods and Experiments

The researchers conducted a systematic search of all clinical trial registrations for EPP from the past five years and selected trial protocols evaluating afamelanotide, dersimelagon, bitopertin, and cimetidine. They analyzed trial designs using the PICO framework (Population, Intervention, Comparator, Outcome) and discussed the findings in light of published results and patient perspectives. The study particularly focused on the comparability of efficacy endpoints, the representativeness of trial populations, the collection methods for safety data, and ethical considerations.

Key Findings and Perspectives

• Current EPP drug trials show significant heterogeneity in efficacy endpoints, population selection, and trial design, making direct comparisons difficult.
• Dersimelagon and afamelanotide use different efficacy endpoints (time to prodromal symptoms vs time to painless sun exposure), which may affect the interpretation of results.
• Bitopertin and cimetidine primarily use reductions in PPIX levels as endpoints, but the correlation between PPIX levels and symptom severity is only evident at high levels, necessitating the inclusion of clinically relevant endpoints.
• Some trials exclude patients with severe anemia or depression, limiting the real-world applicability of the drugs.
• Patient perspectives highlight that requiring sunlight exposure to induce symptoms may raise ethical concerns, especially for children and adolescents.
• The study recommends future trials should directly compare new drugs with afamelanotide to enhance clinical relevance of the data.

Implications and Future Directions

This article emphasizes the need to balance scientific rigor and ethical considerations in clinical trial design, particularly in the context of rare diseases. Future trials should prioritize broader patient inclusion and adopt unified clinically relevant endpoints to enhance data comparability and utility. Additionally, safety monitoring for drugs affecting iron metabolism and liver function should be emphasized for specific subtypes of EPP.

 

Assesses the pathogenic potential of gene variants and provides a reference for analyzing their functional impact.

Learn More

 

Conclusion

This article provides a systematic analysis of the current landscape of clinical trials for erythropoietic protoporphyria (EPP) and identifies significant variability in population selection, efficacy endpoints, and trial design, which hinders direct comparisons of drug efficacy and safety. It highlights ethical and methodological concerns with placebo-controlled trials and protocols requiring sunlight exposure to induce symptoms. The authors, representing patient organizations, suggest that future trials should prioritize head-to-head comparisons with the existing treatment afamelanotide to generate more clinically informative data. Additionally, trial designs should better reflect the real-world disease burden and address the medical needs of vulnerable populations, such as children, patients with severe liver disease, and those with comorbid mental health conditions. This article offers valuable methodological and ethical insights for EPP drug development and is of interest to regulatory agencies, ethics committees, and pharmaceutical companies.

 

Cornelia Dechant, Sebastian Wäscher, Francesca Granata, Rocco Falchetto, and Jasmin Barman-Aksözen. New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective. Orphanet Journal of Rare Diseases.